The resistance of some cancers to the cell-killing effects of radiation therapy may be due to abnormalities in the mitochondria.
In separate studies on CEBPA mutations in AML subtypes, researchers successfully identified a gene known as Sox4 as a potential therapeutic target along with a class of anticancer drugs—histone deacetylase (HDAC) inhibitors—as potential candidates in the treatment of AML subtypes.
Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs).
Researchers have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and they are developing ways to overcome this resistance.
Lymphedema can be accurately assessed through the use of Bioelectrical Impedance Analysis (BIA) ratios, according to a new study.